Photo from Olubukola Ayodele/LinkedIn
Oct 21, 2023, 19:24
Olubukola Ayodele: Day 1 of ESMO 2023 was all about early breast cancer (EBC) for me today
Olubukola Ayodele, Consultant Medical Oncologist at University Hospitals of Leicester NHS trust, shared on LinkedIn:
“Day 1 of ESMO 2023 is over.
It was all about early breast cancer (EBC) for me today.
- MonarchE continues to show benefit with adjuvant Abemaciclib in HR+/HER2- EBC. Median follow up 54 months. All patients have completed 2 years of treatment. Close follow up needed as this cohort tend to relapse after the 5 year mark.
- KN522 also continues to show benefit of the addition of pembrolizumab to chemotherapy for TNBC irrespective of stage.
- New territory: Neoadjuvant immunotherapy in combination with chemotherapy in high risk HR+/HER2- EBC. pCR benefit seen but will it translate to EFS? Also, higher benefit seen in PD-L1 + patients. Would this influence the FDA/EMA approval if benefit is consistent?
More biomarker analysis needed to better select patients in EBC.
However, I’m so happy to see more potential treatment options for patients.”
Source: Olubukola Ayodele/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 18:13
May 8, 2025, 17:53
May 8, 2025, 17:31
May 8, 2025, 17:30